Group DCA

Share this article:
Company Profile
Group DCA is a privately owned interactive agency that was founded in 1999 by pharmaceutical industry veterans Rob Likoff and Jack Davis in response to an industry need:

Create a more effective way to engage healthcare providers.

Group DCA and its divisions leverage the strengths of the Internet, multimedia, tablet PCs, direct mail and proprietary software called DIAGRAM (DIAlog, GRAphic, Motions) to deliver breakthrough solutions that immerse healthcare providers in a worthwhile, enjoyable and interactive dialog online, in the mail and in their office.

Group DCA has expanded the use of that proven model to deliver award-winning content in “active learning” sessions (Learning by doing), to doctors (in every specialty, and to KOLs and speakers), nurses, pharmacists, patients and caregivers. Programs have also been created to train pharmaceutical sales reps.

Group DCA programs yield actionable response data, change behavior and produce remarkable ROI.

Services and Offerings
Group DCA is the parent company of five, award-winning, specialized divisions offering these interactive services:  
  • Cue—Patient education, adherence and persistency programs
  • Graphic Details—Promotional programs, i.e. eDetailing (online & convention-based)  
  • iLights—Pharmaceutical manufacturer sponsored online healthcare publishing  
  • Insight Exchange—Online KOL-focused programs
  • Park Street Research—Online market research
Group DCA partners with direct mail veterans D & R Communications to offer POWERXposure—seamless coordination of promotional touch-points (direct mail, eMarketing, live meetings) that elicit even greater physician response.

Case Study
eDetailing ROI Report - March 8, 2007
Product Category: Diabetes Care
The Program
  • 2 waves of eDetailing
  • 1,200+ completions per wave
ROI measurement
  • All ROI analysis performed by third-party (Bullseye ROI, Ft. Lauderdale) in conjunction with analytics team at client company
  • Reports typically generated at 6, 12 and 18-months program launch

Methodology
  • The analysis methodology is a physician matched pair design
  • Each participating doctor (test doctor) is matched to a control doctor such that they have very similar “Product” prescribing levels and patterns
  • A 6 or 12-month period prior to the start of the program was used as the match period
  • “Product” prescription data was available for use in matching
  • Physicians were also matched on prior call activity—Prior call/Rx activity represents >90% of “variability”
Results
Two Waves (n=767)
  • 51.1% NRx increase
  • 5-month ROI: 301%
  • 12-month ROI (proj): 692%
  • 24-month ROI (proj): 1484%
Statistically significant at 99%
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...